Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Christian S. Hinrichs, Zachary A. Borman, Luca Gattinoni, Zhiya Yu, William Burns, Jianping Huang, Christopher A. Klebanoff, Laura A. Johnson, Sid P. Kerkar, Shicheng Yang, Pawel Muranski, Douglas C. Palmer, Christopher D. Scott, Richard A. Morgan, Paul F. Robbins, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Cluster of differentiation (CD)8+ T cells exist as naive, central memory, and effector memory subsets, and any of these populations can be genetically engineered into tumor-reactive effector cells for adoptive immunotherapy. However, the optimal subset from which to derive effector CD8+ T cells for patient treatments is controversial and understudied. We investigated human CD8+ T cells and found that naive cells were not only the most abundant subset but also the population most capable of in vitro expansion and T-cell receptor transgene expression. Despite increased expansion, naive-derived cells displayed minimal effector differentiation, a quality associated with greater efficacy after cell infusion. Similarly, the markers of terminal differentiation, killer cell lectin-like receptor G1 and CD57, were expressed at lower levels in cells of naive origin. Finally, naive-derived effector cells expressed higher CD27 and retained longer telomeres, characteristics that suggest greater proliferative potential and that have been linked to greater efficacy in clinical trials. Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy.

Original languageEnglish (US)
Pages (from-to)808-814
Number of pages7
JournalBlood
Volume117
Issue number3
DOIs
StatePublished - Jan 20 2011
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
T-cells
T-Lymphocytes
Data storage equipment
NK Cell Lectin-Like Receptors
Patient treatment
T-Cell Antigen Receptor
Tumors
Differentiation Antigens
Telomere
Transgenes
Population
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. / Hinrichs, Christian S.; Borman, Zachary A.; Gattinoni, Luca; Yu, Zhiya; Burns, William; Huang, Jianping; Klebanoff, Christopher A.; Johnson, Laura A.; Kerkar, Sid P.; Yang, Shicheng; Muranski, Pawel; Palmer, Douglas C.; Scott, Christopher D.; Morgan, Richard A.; Robbins, Paul F.; Rosenberg, Steven A.; Restifo, Nicholas P.

In: Blood, Vol. 117, No. 3, 20.01.2011, p. 808-814.

Research output: Contribution to journalArticle

Hinrichs, CS, Borman, ZA, Gattinoni, L, Yu, Z, Burns, W, Huang, J, Klebanoff, CA, Johnson, LA, Kerkar, SP, Yang, S, Muranski, P, Palmer, DC, Scott, CD, Morgan, RA, Robbins, PF, Rosenberg, SA & Restifo, NP 2011, 'Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy', Blood, vol. 117, no. 3, pp. 808-814. https://doi.org/10.1182/blood-2010-05-286286
Hinrichs, Christian S. ; Borman, Zachary A. ; Gattinoni, Luca ; Yu, Zhiya ; Burns, William ; Huang, Jianping ; Klebanoff, Christopher A. ; Johnson, Laura A. ; Kerkar, Sid P. ; Yang, Shicheng ; Muranski, Pawel ; Palmer, Douglas C. ; Scott, Christopher D. ; Morgan, Richard A. ; Robbins, Paul F. ; Rosenberg, Steven A. ; Restifo, Nicholas P. / Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. In: Blood. 2011 ; Vol. 117, No. 3. pp. 808-814.
@article{27bd4273974c439c8d491ad17da96971,
title = "Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy",
abstract = "Cluster of differentiation (CD)8+ T cells exist as naive, central memory, and effector memory subsets, and any of these populations can be genetically engineered into tumor-reactive effector cells for adoptive immunotherapy. However, the optimal subset from which to derive effector CD8+ T cells for patient treatments is controversial and understudied. We investigated human CD8+ T cells and found that naive cells were not only the most abundant subset but also the population most capable of in vitro expansion and T-cell receptor transgene expression. Despite increased expansion, naive-derived cells displayed minimal effector differentiation, a quality associated with greater efficacy after cell infusion. Similarly, the markers of terminal differentiation, killer cell lectin-like receptor G1 and CD57, were expressed at lower levels in cells of naive origin. Finally, naive-derived effector cells expressed higher CD27 and retained longer telomeres, characteristics that suggest greater proliferative potential and that have been linked to greater efficacy in clinical trials. Thus, these data suggest that naive cells resist terminal differentiation, or {"}exhaustion,{"} maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy.",
author = "Hinrichs, {Christian S.} and Borman, {Zachary A.} and Luca Gattinoni and Zhiya Yu and William Burns and Jianping Huang and Klebanoff, {Christopher A.} and Johnson, {Laura A.} and Kerkar, {Sid P.} and Shicheng Yang and Pawel Muranski and Palmer, {Douglas C.} and Scott, {Christopher D.} and Morgan, {Richard A.} and Robbins, {Paul F.} and Rosenberg, {Steven A.} and Restifo, {Nicholas P.}",
year = "2011",
month = "1",
day = "20",
doi = "10.1182/blood-2010-05-286286",
language = "English (US)",
volume = "117",
pages = "808--814",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

AU - Hinrichs, Christian S.

AU - Borman, Zachary A.

AU - Gattinoni, Luca

AU - Yu, Zhiya

AU - Burns, William

AU - Huang, Jianping

AU - Klebanoff, Christopher A.

AU - Johnson, Laura A.

AU - Kerkar, Sid P.

AU - Yang, Shicheng

AU - Muranski, Pawel

AU - Palmer, Douglas C.

AU - Scott, Christopher D.

AU - Morgan, Richard A.

AU - Robbins, Paul F.

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

PY - 2011/1/20

Y1 - 2011/1/20

N2 - Cluster of differentiation (CD)8+ T cells exist as naive, central memory, and effector memory subsets, and any of these populations can be genetically engineered into tumor-reactive effector cells for adoptive immunotherapy. However, the optimal subset from which to derive effector CD8+ T cells for patient treatments is controversial and understudied. We investigated human CD8+ T cells and found that naive cells were not only the most abundant subset but also the population most capable of in vitro expansion and T-cell receptor transgene expression. Despite increased expansion, naive-derived cells displayed minimal effector differentiation, a quality associated with greater efficacy after cell infusion. Similarly, the markers of terminal differentiation, killer cell lectin-like receptor G1 and CD57, were expressed at lower levels in cells of naive origin. Finally, naive-derived effector cells expressed higher CD27 and retained longer telomeres, characteristics that suggest greater proliferative potential and that have been linked to greater efficacy in clinical trials. Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy.

AB - Cluster of differentiation (CD)8+ T cells exist as naive, central memory, and effector memory subsets, and any of these populations can be genetically engineered into tumor-reactive effector cells for adoptive immunotherapy. However, the optimal subset from which to derive effector CD8+ T cells for patient treatments is controversial and understudied. We investigated human CD8+ T cells and found that naive cells were not only the most abundant subset but also the population most capable of in vitro expansion and T-cell receptor transgene expression. Despite increased expansion, naive-derived cells displayed minimal effector differentiation, a quality associated with greater efficacy after cell infusion. Similarly, the markers of terminal differentiation, killer cell lectin-like receptor G1 and CD57, were expressed at lower levels in cells of naive origin. Finally, naive-derived effector cells expressed higher CD27 and retained longer telomeres, characteristics that suggest greater proliferative potential and that have been linked to greater efficacy in clinical trials. Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=78751689288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751689288&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-286286

DO - 10.1182/blood-2010-05-286286

M3 - Article

VL - 117

SP - 808

EP - 814

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -